U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C59H84N18O14
Molecular Weight 1269.4105
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GOSERELIN

SMILES

CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O

InChI

InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

HIDE SMILES / InChI

Molecular Formula C59H84N18O14
Molecular Weight 1269.4105
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 4
Optical Activity UNSPECIFIED

Description

Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.82 nM [IC50]
1.6 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOLADEX
Palliative
ZOLADEX

Cmax

ValueDoseCo-administeredAnalytePopulation
1.46 ng/mL
3.6 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens
2.84 ng/mL
3.6 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens
7.79 μg/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
13.9 μg/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
9.5 μg/L
250 μg 1 times / day multiple, subcutaneous
GOSERELIN plasma
Homo sapiens
7.5 μg/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
3 ng/mL
3.6 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens
8.85 ng/mL
10.8 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
18.5 ng × day/mL
3.6 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens
27.8 ng × day/mL
3.6 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens
36.9 μg × h/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
41.3 μg × h/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
44 μg × h/L
250 μg 1 times / day multiple, subcutaneous
GOSERELIN plasma
Homo sapiens
44.5 μg × h/L
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
4.2 h
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
2.3 h
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens
5 h
250 μg 1 times / day multiple, subcutaneous
GOSERELIN plasma
Homo sapiens
4.6 h
250 μg single, subcutaneous
GOSERELIN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
73%
10.8 mg single, subcutaneous
GOSERELIN plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
ZOLADEX (Goserelin), at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician
Route of Administration: Other
In Vitro Use Guide
Goserelin significantly inhibited LNCaP cell proliferation at doses between 10(-9)-10(-6) M.
Substance Class Chemical
Record UNII
0F65R8P09N
Record Status Validated (UNII)
Record Version